Farrukh T. Awan
- Genetics top 0.2%
- Pathology and Forensic Medicine top 0.5%
- Immunology top 2%
- Oncology top 5%
- Hematology top 1%
- Co-authors
- John C. ByrdJennifer A. WoyachMehdi HamadaniJeffrey A. JonesKami J. MaddocksLeslie A. AndritsosKerry A. RogersNatarajan Muthusamy
- Topics
- Chronic Lymphocytic Leukemia Research (127 papers)Lymphoma Diagnosis and Treatment (92 papers)Chronic Myeloid Leukemia Treatments (36 papers)
- Journals
- New England Journal of MedicineJournal of Clinical InvestigationJournal of Clinical Oncology
- Partner nations
- United StatesFranceGermany
In The Last Decade
Farrukh T. Awan
184 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 101
- Genetics 2.0k
- Pathology and Forensic Medicine 1.6k
- Immunology 1.3k
- Oncology 976
- Hematology 935
Countries citing papers authored by Farrukh T. Awan
This map shows the geographic impact of Farrukh T. Awan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farrukh T. Awan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farrukh T. Awan more than expected).
Fields of papers citing papers by Farrukh T. Awan
This network shows the impact of papers produced by Farrukh T. Awan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farrukh T. Awan. The network helps show where Farrukh T. Awan may publish in the future.
Co-authorship network of co-authors of Farrukh T. Awan
This figure shows the co-authorship network connecting the top 25 collaborators of Farrukh T. Awan. A scholar is included among the top collaborators of Farrukh T. Awan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farrukh T. Awan. Farrukh T. Awan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 0 | |
| 3 | 3 | |
| 4 | 2 | |
| 5 | 6 | |
| 6 | 0 | |
| 7 | 4 | |
| 8 | 11 | |
| 9 | 46 | |
| 10 | 3 | |
| 11 | 144 | |
| 12 | 2 | |
| 13 | 23 | |
| 14 | 1 | |
| 15 | 0 | |
| 16 | 30 | |
| 17 | 4 | |
| 18 | 45 | |
| 19 | 11 | |
| 20 | 117 |
About Farrukh T. Awan
Farrukh T. Awan is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 199 papers that have together received 3.7k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (127 papers), Lymphoma Diagnosis and Treatment (92 papers) and Chronic Myeloid Leukemia Treatments (36 papers). The work is most often cited by research in Genetics (2.0k citations), Pathology and Forensic Medicine (1.6k citations) and Hematology (935 citations). Farrukh T. Awan has collaborated with scholars based in United States, France and Germany. Frequent co-authors include John C. Byrd, Jennifer A. Woyach, Mehdi Hamadani, Jeffrey A. Jones, Kami J. Maddocks, Leslie A. Andritsos, Kerry A. Rogers, Natarajan Muthusamy, Joseph M. Flynn and Carolyn Cheney. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.